Brief prescribing information
Download the Brief Prescribing Information for MabThera.
MabThera is the new standard of care in CLL. MabThera plus chemotherapy significantly improves PFS compared with chemotherapy alone in first-line CLL, maximising remission for these patients.
MabThera maintenance therapy prolongs response to induction chemotherapy and is approved for patients with relapsed/refractory follicular lymphoma.